$2M Small Business Innovation Research Direct to Phase II Award Funds Therapeutic Development, Testing at Stingray Therapeutics, Translational Genomics Research Institute
PHOENIX, Arizona, Oct. 5 (TNSawa) -- The Translational Genomics Research Institute issued the following news release on Oct. 4, 2022:
The Translational Genomics Research Institute, Part of City of Hope, and Stingray Therapeutics, Inc. of Dallas and Houston, Texas today announced a Small Business Innovation Research (SBIR) accelerated direct to phase II award of $2 Million. The NIH award, known as America's Seed Fund, provides support to early-stage businesses to bring scientific inn . . .
The Translational Genomics Research Institute, Part of City of Hope, and Stingray Therapeutics, Inc. of Dallas and Houston, Texas today announced a Small Business Innovation Research (SBIR) accelerated direct to phase II award of $2 Million. The NIH award, known as America's Seed Fund, provides support to early-stage businesses to bring scientific inn . . .